| Literature DB >> 32482792 |
Ahmad Masri1, Syed Bukhari2, Yvonne S Eisele2, Prem Soman3.
Abstract
Transthyretin and light-chain amyloidosis are the 2 main causes of cardiac amyloidosis. Recent developments in molecular imaging have transformed our ability to diagnose transthyretin cardiac amyloidosis noninvasively and unmasked a hitherto unrecognized prevalence of the disease. This review summarizes the current and evolving imaging approaches, their molecular structural basis, and the gaps in imaging capabilities that have arisen as a result of parallel developments in pharmacotherapy delivering the first effective treatment options for this condition.Entities:
Keywords: ATTR; SPECT; bone-seeking tracers; cardiac amyloidosis; molecular imaging
Mesh:
Year: 2020 PMID: 32482792 PMCID: PMC9374028 DOI: 10.2967/jnumed.120.245381
Source DB: PubMed Journal: J Nucl Med ISSN: 0161-5505 Impact factor: 11.082